CLINICAL TRIALS PROFILE FOR CLOLAR

All Clinical Trials for Clolar

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00067028 ↗	Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)	Completed	Genzyme, a Sanofi Company	Phase 2	2003-12-01	The goal is to compare the drug combinations clofarabine/idarubicin/ara-C, clofarabine/ara-C, and clofarabine/idarubicin in the treatment of patients with Acute Myeloid Leukemia, high-grade MDS, or myeloid blast phase of Chronic Myeloid Leukemia who have relapsed following their initial therapy.
NCT00067028 ↗	Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)	Completed	M.D. Anderson Cancer Center	Phase 2	2003-12-01	The goal is to compare the drug combinations clofarabine/idarubicin/ara-C, clofarabine/ara-C, and clofarabine/idarubicin in the treatment of patients with Acute Myeloid Leukemia, high-grade MDS, or myeloid blast phase of Chronic Myeloid Leukemia who have relapsed following their initial therapy.
NCT00081887 ↗	Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia	Terminated	Genzyme, a Sanofi Company	Phase 1	2004-05-01	Primary Objectives: 1. To determine the maximum tolerated dose (MTD) of clofarabine in Chronic Lymphocytic Leukemia (CLL). 2. To determine the toxicity profile of clofarabine in CLL. 3. To investigate the plasma clofarabine and cellular clofarabine triphosphate pharmacology profile of clofarabine in CLL.
NCT00081887 ↗	Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia	Terminated	M.D. Anderson Cancer Center	Phase 1	2004-05-01	Primary Objectives: 1. To determine the maximum tolerated dose (MTD) of clofarabine in Chronic Lymphocytic Leukemia (CLL). 2. To determine the toxicity profile of clofarabine in CLL. 3. To investigate the plasma clofarabine and cellular clofarabine triphosphate pharmacology profile of clofarabine in CLL.
NCT00088218 ↗	Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).	Completed	Genzyme, a Sanofi Company	Phase 2	2004-07-01	The goal of this clinical research study is to study how effective treatments with clofarabine alone and clofarabine given in combination with ara-C are in the treatment of leukemia and high-risk myelodysplastic syndrome (MDS) in patients who are 60 years or older. The safety of these treatments will also be compared.
NCT00088218 ↗	Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).	Completed	M.D. Anderson Cancer Center	Phase 2	2004-07-01	The goal of this clinical research study is to study how effective treatments with clofarabine alone and clofarabine given in combination with ara-C are in the treatment of leukemia and high-risk myelodysplastic syndrome (MDS) in patients who are 60 years or older. The safety of these treatments will also be compared.

Clinical Trial Conditions for Clolar

Condition Name

Condition Name for Clolar
Intervention	Trials
Leukemia	21
Acute Myeloid Leukemia	18
Myelodysplastic Syndrome	12
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities	8

Condition MeSH

Condition MeSH for Clolar
Intervention	Trials
Leukemia	54
Leukemia, Myeloid, Acute	39
Leukemia, Myeloid	36
Myelodysplastic Syndromes	23

Clinical Trial Locations for Clolar

Trials by Country

Trials by Country for Clolar
Location	Trials
United States	290
Canada	16
Australia	5
Israel	2
India	2

Trials by US State

Trials by US State for Clolar
Location	Trials
Texas	32
Washington	15
California	12
Tennessee	11
New York	11

Clinical Trial Progress for Clolar

Clinical Trial Phase

Clinical Trial Phase for Clolar
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	35
Phase 1/Phase 2	13

Clinical Trial Status

Clinical Trial Status for Clolar
Clinical Trial Phase	Trials
Completed	32
Terminated	14
Active, not recruiting	8

Clinical Trial Sponsors for Clolar

Sponsor Name

Sponsor Name for Clolar
Sponsor	Trials
M.D. Anderson Cancer Center	25
National Cancer Institute (NCI)	24
Genzyme, a Sanofi Company	20

Sponsor Type

Sponsor Type for Clolar
Sponsor	Trials
Other	76
Industry	28
NIH	25

Clolar Market Analysis and Financial Projection

Last updated: April 28, 2026

Clolar (clofazimine): clinical-trial update, market analysis, and 2026 to 2035 projection

What is Clolar and where does it sit in the development pipeline?

Clolar is the brand name associated with clofazimine (drug class: antimycobacterial; related to the clofazimine program historically linked to tuberculosis indications). This response is limited to market, trial, and projection content that can be supported with traceable, dated information.

No complete, verifiable clinical-trial update, current study identifiers, enrollment status, or materially supported market and pricing facts were provided in the prompt. With those constraints, a complete and accurate end-to-end update cannot be produced.

What is the latest clinical-trials status for Clolar?

No verifiable, dated trial status (study names/IDs, registry links, phase, arms, endpoints, enrollment counts, or results) is available in the information provided. A “clinical trials update” requires registry-backed specifics (e.g., ClinicalTrials.gov/NHS, EU CTR, ISRCTN) and dated milestones (first patient in, recruitment status change, topline reads, regulatory submissions).

What is the addressable market for clofazimine / Clolar and how will it monetize?

A market analysis requires hard inputs: indication targets, prevalence/incidence, lines of therapy, expected uptake curves, pricing references, reimbursement pathways, and competitive set. None of these inputs are present in the prompt.

How do you project revenue through 2035 for Clolar?

Revenue projections require assumptions grounded in:

• clinical success probability by phase and indication
• target product profile and label scope
• treatment duration and dosing regimen
• penetration by setting (public TB programs, private markets, hospital formularies)
• realized pricing and gross-to-net conversion
• patent and exclusivity timeline, and expected generic or competing entry

No such dated and attributable facts are included in the prompt; a complete projection would not meet the “complete and accurate response” standard.

Key Takeaways

• A complete, accurate clinical-trials update for Clolar requires dated registry facts (trial IDs, phases, recruitment/enrollment status, endpoints, and results).
• A complete, accurate market analysis and 2026 to 2035 projection requires documented pricing, label assumptions, epidemiology targets, uptake drivers, and competitive entry timing.
• The prompt provides insufficient traceable inputs to generate an authoritative Bloomberg-style update with verifiable numbers.

FAQs

1. Is Clolar approved in major markets?
   Not specified in the provided information.

2. Which TB regimen lines is clofazimine expected to target?
   Not specified in the provided information.

3. What phase are Clolar studies in right now?
   Not specified in the provided information.

4. What is the expected pricing and reimbursement pathway for Clolar?
   Not specified in the provided information.

5. What competitors could limit Clolar uptake?
   Not specified in the provided information.

References

No sources were provided or cited in the prompt.